Could a JAK inhibitor tame chronic hives? new trial aims to find out
Disease control
Terminated
This study tested whether the drug ritlecitinib can safely control chronic spontaneous urticaria (CSU) — hives and itching lasting over six weeks. The trial planned to enroll adults aged 18–65 who would take the drug daily for 12 weeks and track their symptoms. However, the study…
Phase: PHASE2 • Sponsor: Ahuva D Cices • Aim: Disease control
Last updated Apr 24, 2026 16:20 UTC